Biomerica (BMRA) vs Insight Molecular Diagnostics (IMDX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Insight Molecular Diagnostics (IMDX) has outperformed Biomerica (BMRA) over the past year, losing 10.9% versus a loss of 34.4%. Over five years, IMDX leads with a -94.9% price change compared with -95.7% for BMRA. Insight Molecular Diagnostics is the larger company by market cap ($107.3 million vs $8.7 million), about 12.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BMRA | IMDX |
|---|---|---|
| Share price | $1.89 | $3.28 |
| Market cap | $8.69M | $107.34M |
| 1-day change | -0.53% | -5.20% |
| YTD return | -25.00% | -56.27% |
| 1-year return | -34.38% | -10.87% |
| 5-year return | -95.74% | -94.91% |
| Forward P/E | 4.85 | — |
| EPS (TTM) | $-1.30 | $-1.52 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.21 | $8.51 |
| 52-week low | $1.45 | $2.42 |
| Distance from 52-week high | -41.12% | -61.46% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +151.52% |
| Average volume | 70.88K | 232.87K |
| Shares outstanding | 4.60M | 32.72M |
| Employees | 50 | 55 |
| Sector | Healthcare | Healthcare |
| Industry | Medical Devices | Diagnostics & Research |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Insight Molecular Diagnostics is about 12.3 times larger than Biomerica by market value ($107.34M vs $8.69M).
- IMDX has outperformed BMRA by 23.5 percentage points over the past year.
About Biomerica
BMRA stock →Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing of diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases in North America, Asia, Europe, the Middle East, and South America. The company offers diagnostic test kits are used to analyze blood, urine, nasal, or fecal material from patients to aid in the diagnosis of diseases, food intolerances, and other medical conditions, as well as detect and measure the presence and levels of specific bacteria, hormones, antibodies, antigens, and other substances that may exist in the human body at extremely low concentrations through clinical laboratories and in point-of-care settings, including physicians' offices and over-the-counter channels.
Healthcare · Medical Devices · 50 employees
About Insight Molecular Diagnostics
IMDX stock →Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally.
Healthcare · Diagnostics & Research · 55 employees
BMRA vs IMDX FAQ
Which is bigger, Biomerica or Insight Molecular Diagnostics?
Insight Molecular Diagnostics (IMDX) is larger, with a market capitalization of $107.34M compared with $8.69M for Biomerica (BMRA).
Which stock has performed better over the past year, BMRA or IMDX?
IMDX returned -10.87% over the past 12 months, compared with -34.38% for BMRA (price return, excluding dividends). Past performance does not predict future results.
Are Biomerica and Insight Molecular Diagnostics in the same industry?
Both are in the Healthcare sector, but in different industries: Medical Devices for Biomerica and Diagnostics & Research for Insight Molecular Diagnostics.